For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the kymriah industry by 2029?
The kymriah market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to an increase in the prevalence of cancer, an increase in public-private investments in the healthcare sector, a rise in cases of leukemia, a rise in r and d investments in drug discovery, increase in healthcare infrastructure.
The kymriah market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing number of clinical trials, growing demand for personalized and targeted therapies, rising rate of people being diagnosed, growing investment in biotech, and increasing demand for effective treatment. Major trends in the forecast period include technological advancements in personalized medicine, artificial intelligence (AI) in CAR T-cell therapy, advances in manufacturing, ongoing research into optimizing the efficacy, demand for combination therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20135&type=smp
Which industry-specific innovations are acting as key drivers for the kymriah market?
The rising prevalence of hematological cancer is expected to propel the growth of the kymriah market going forward. Hematological cancer includes cancers that impact the blood, bone marrow, lymph nodes, and lymphatic system. The rise in hematological cancer can be attributed to several factors, including an aging population, genetic factors, immune system disorders, and lifestyle factors. Kymriah is used in hematological cancers to treat certain types of leukemia and lymphoma by utilizing CAR-T cell therapy to target and destroy cancerous cells. For instance, in September 2024, according to the Leukemia & Lymphoma Society (LLS), a US-based charitable organization dedicated to fighting blood cancer worldwide, in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every 3 minutes. In 2024, it is estimated that 187,740 people will be diagnosed with these hematological cancers. Therefore, the rising prevalence of hematological cancer is driving the growth of the kymriah market.
Which segment currently leads the kymriah market in terms of revenue share?
The kymriah market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Intravenous), Customized Patient-Specific Formulations
2) By Indication: Treatment Of B-cell Acute Lymphoblastic Leukemia, Treatment Of Diffuse Large B-cell Lymphoma, Treatment Of Follicular Lymphoma, Other Potential Indications
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Oncology Clinics, Hematology Treatment Centers, Research Institutions
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/kymriah-global-market-report
What future trends will impact the direction of the kymriah industry?
The key trend in the kymriah market is the emphasis on advancing CAR-T cell therapies to improve treatment effectiveness and broaden the eligible patient base for various hematologic cancers. CAR-T cell therapies involve genetically modifying a patient’s T cells to express chimeric antigen receptors (CAR), enabling them to identify and eliminate cancer cells, particularly in specific leukemias and lymphomas. For instance, in May 2022, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for kymriah (tisagenlecleucel). This therapy is designed to treat adult patients with relapsed or refractory follicular lymphoma after they have undergone two or more lines of systemic therapy. Kymriah has demonstrated the potential for lasting results, with 86% of patients responding positively and 68% achieving complete remission. Its ability to provide durable responses, particularly in high-risk patients, distinguishes it from other treatments. Notably, kymriah is currently the only CAR-T cell therapy approved for both adult and pediatric patients across multiple indications.
Who are the top competitors in the global kymriah market?
Major companies operating in the kymriah market include Novartis AG
What regional dynamics are shaping the future of the global kymriah market?
North America was the largest region in the kymriah market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kymriah market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Kymriah Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20135
Need Customized Data On Kymriah Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20135&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
